Mouse Models of CMML

被引:2
作者
Belotserkovskaya, Ekaterina [1 ]
Demidov, Oleg [1 ,2 ]
机构
[1] Russian Acad Sci, Inst Cytol, Lab Mol Med, 4 Tikhoretskii Prospect, St Petersburg 194064, Russia
[2] Lab Excellence LipSTIC & Label Ligue Natl Canc, 7 Blvd Jeanne dArc, F-21000 Dijon, France
基金
俄罗斯科学基金会;
关键词
chronic myelomonocytic leukemia; CMML; mouse models; CHRONIC MYELOMONOCYTIC LEUKEMIA; WORLD-HEALTH-ORGANIZATION; COLONY-STIMULATING FACTOR; CYTOGENETIC RISK STRATIFICATION; HEMATOPOIETIC STEM; MYELODYSPLASTIC SYNDROMES; MYELOID NEOPLASMS; SETBP1; MUTATIONS; GENE-MUTATIONS; TET2; GENE;
D O I
10.3390/ijms222111510
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Chronic myelomonocytic leukemia (CMML) is a rare and challenging type of myeloproliferative neoplasm. Poor prognosis and high mortality, associated predominantly with progression to secondary acute myeloid leukemia (sAML), is still an unsolved problem. Despite a growing body of knowledge about the molecular repertoire of this disease, at present, the prognostic significance of CMML-associated mutations is controversial. The absence of available CMML cell lines and the small number of patients with CMML make pre-clinical testing and clinical trials complicated. Currently, specific therapy for CMML has not been approved; most of the currently available therapeutic approaches are based on myelodysplastic syndrome (MDS) and other myeloproliferative neoplasm (MNP) studies. In this regard, the development of the robust CMML animal models is currently the focus of interest. This review describes important studies concerning animal models of CMML, examples of methodological approaches, and the obtained hematologic phenotypes.
引用
收藏
页数:14
相关论文
共 102 条
  • [1] Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents
    Alfonso, Ana
    Montalban-Bravo, Guillermo
    Takahashi, Koichi
    Jabbour, Elias J.
    Kadia, Tapan
    Ravandi, Farhad
    Cortes, Jorge
    Estrov, Zeev
    Borthakur, Gautam
    Pemmaraju, Naveen
    Konopleva, Marina
    Bueso-Ramos, Carlos
    Pierce, Sherry
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2017, 92 (07) : 599 - 606
  • [2] Update on the pathologic diagnosis of chronic myelomonocytic leukemia
    Arber, Daniel A.
    Orazi, Attilio
    [J]. MODERN PATHOLOGY, 2019, 32 (06) : 732 - 740
  • [3] The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
    Arber, Daniel A.
    Orazi, Attilio
    Hasserjian, Robert
    Thiele, Jurgen
    Borowitz, Michael J.
    Le Beau, Michelle M.
    Bloomfield, Clara D.
    Cazzola, Mario
    Vardiman, James W.
    [J]. BLOOD, 2016, 127 (20) : 2391 - 2405
  • [4] Transcription intermediary factor 1γ is a tumor suppressor in mouse and human chronic myelomonocytic leukemia
    Aucagne, Romain
    Droin, Nathalie
    Paggetti, Jerome
    Lagrange, Brice
    Largeot, Anne
    Hammann, Arlette
    Bataille, Amandine
    Martin, Laurent
    Yan, Kai-Ping
    Fenaux, Pierre
    Losson, Regine
    Solary, Eric
    Bastie, Jean-Noel
    Delva, Laurent
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2011, 121 (06) : 2361 - 2370
  • [5] The structural and functional basis of cytokine receptor activation: Lessons from the common beta subunit of the granulocyte-macrophage colony-stimulating factor, interleukin-3 (IL-3), and IL-5 receptors
    Bagley, CJ
    Woodcock, JM
    Stomski, FC
    Lopez, AF
    [J]. BLOOD, 1997, 89 (05) : 1471 - 1482
  • [6] TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients
    Bejar, Rafael
    Lord, Allegra
    Stevenson, Kristen
    Bar-Natan, Michal
    Perez-Ladaga, Albert
    Zaneveld, Jacques
    Wang, Hui
    Caughey, Bennett
    Stojanov, Petar
    Getz, Gad
    Garcia-Manero, Guillermo
    Kantarjian, Hagop
    Chen, Rui
    Stone, Richard M.
    Neuberg, Donna
    Steensma, David P.
    Ebert, Benjamin L.
    [J]. BLOOD, 2014, 124 (17) : 2705 - 2712
  • [7] THE CHRONIC MYELOID LEUKEMIAS - GUIDELINES FOR DISTINGUISHING CHRONIC GRANULOCYTIC, ATYPICAL CHRONIC MYELOID, AND CHRONIC MYELOMONOCYTIC LEUKEMIA - PROPOSALS BY THE FRENCH-AMERICAN-BRITISH-COOPERATIVE-LEUKEMIA-GROUP
    BENNETT, JM
    CATOVSKY, D
    DANIEL, MT
    FLANDRIN, G
    GALTON, DAG
    GRALNICK, H
    SULTAN, C
    COX, C
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1994, 87 (04) : 746 - 754
  • [8] Trends of incidence and survival of patients with chronic myelomonocytic leukemia between 1999 and 2014: A comparison between Swiss and American population-based cancer registries
    Benzarti, Sonia
    Daskalakis, Michael
    Feller, Anita
    Bacher, Vera Ulrike
    Schnegg-Kaufmann, Annatina
    Ruefer, Axel
    Holbro, Andreas
    Schmidt, Adrian
    Benz, Rudolf
    Solenthaler, Max
    Stussi, Georg
    Arndt, Volker
    Bonadies, Nicolas
    Adam, M.
    Curjuric, I
    Staehelin, K.
    Perren, A.
    Hayoz, C. Egger
    Bouchardy, C.
    Mousavi, M.
    Diebold, J.
    Bulliard, Jean-Luc
    Maspoli, Manuela
    Schmidt, A.
    Bordoni, A.
    Konzelmann, I
    Blanc-Moya, Rafael
    Rohrmann, S.
    [J]. CANCER EPIDEMIOLOGY, 2019, 59 : 51 - 57
  • [9] RUNX1 mutations promote leukemogenesis of myeloid malignancies in ASXL1-mutated leukemia
    Bera, Rabindranath
    Chiu, Ming-Chun
    Huang, Ying-Jung
    Lin, Tung-Huei
    Kuo, Ming-Chung
    Shih, Lee-Yung
    [J]. JOURNAL OF HEMATOLOGY & ONCOLOGY, 2019, 12 (01)
  • [10] Nf1 and Gmcsf interact in myeloid leukemogenesis
    Birnbaum, RA
    O'Marcaigh, A
    Wardak, Z
    Zhang, YY
    Dranoff, G
    Jacks, T
    Clapp, DW
    Shannon, KM
    [J]. MOLECULAR CELL, 2000, 5 (01) : 189 - 195